Best Cannabis Stocks

Before any name, the risks. Cannabis is not a normal sector, and reading these first is what keeps a small research position from turning into an outsized bet on a category that has repeatedly disappointed.

• Federal illegality is the whole problem. Cannabis is still illegal under US federal law even where states have legalized it. The entire bull case rests on reform (rescheduling, banking access, or legalization) that has been promised and delayed for years. If reform stalls again, so does the thesis.
• 280E taxation crushes profitability. Section 280E bars plant-touching businesses from deducting normal operating expenses, so their effective tax rates run far above other industries. Even operators that grow revenue struggle to turn it into profit.
• No normal banking or exchange access. Federal illegality limits access to banks, credit, and payment processing, and pushes most US operators onto OTC markets instead of the NYSE or Nasdaq. That means thinner liquidity, wider spreads, lighter disclosure, and higher costs.
• Chronic dilution. Many operators fund persistent losses by issuing new shares, so existing holders are steadily diluted. A business can grow while its per-share value falls.
• Weak long-term performance and delisting risk. The sector is down heavily from its 2018-2021 peak, many names off more than 90%, and the smallest names risk delisting. This category has rewarded speculation and timing far more than patience.

None of this is a recommendation for or against the sector. It is the honest baseline any cannabis investor should carry into their own research before looking at a single ticker.

If you do research the sector, it helps to know that “cannabis stocks” are really several very different kinds of business with different risks. The names below appear only as segment examples so you can see what each group is, never as picks or recommendations. Any ticker linked here has its own page with more detail; US multi-state operators are named without links because they trade OTC and have no page here.

The same cautions in one place, so you can weigh what you would be taking on rather than read a list of tickers as a ranking. This is the lens the whole page is built around; verify current figures before acting.

If your interest is the theme rather than the gamble, there are lower-risk ways to be near it without concentrating in the most speculative names. None of these is advice; they are the more diversified alternatives people commonly consider.

• Keep any cannabis position small. If you take one at all, sizing it as a small, high-risk slice of a diversified portfolio limits the damage if the sector stays weak. Speculative allocations are the kind you can afford to lose.
• Prefer a diversified fund over a single name. A cannabis ETF spreads single-stock risk across many operators, which removes the danger of picking one company that fails, though it keeps the sector-wide risks.
• Look at ancillary businesses. Real estate, technology, and equipment names that sell into the industry avoid some of the direct legal and 280E problems that plant-touching operators face, though they carry tenant and counterparty risk.
• Consider large, established consumer companies with optionality. Some beverage, tobacco, and pharmaceutical companies have taken cannabis stakes or positioned for reform while running profitable core businesses, so the cannabis exposure is a small part of a durable company rather than the whole bet.

The point is not that cannabis exposure is forbidden, only that if you want it, the diversified and adjacent routes carry less single-name risk than concentrating in a speculative OTC operator.

A ticker off a list is not a plan. If you decide to research this sector, the discipline that matters is sizing, diversification, and seeing how a speculative sleeve would sit inside your whole portfolio. That is what Walnut is built for, and it never tells you what to buy.

• Size the position first. Decide what small percentage, if any, a speculative theme deserves before you look at names, so the sector cannot dominate your portfolio by accident.
• Diversify beyond the theme. Hold cannabis, if at all, alongside broad, durable holdings so one failing sector does not sink the whole account.
• Set target weights. Assign each holding a percentage that sums to 100, so concentration is a choice you made rather than an accident of which stock moved.
• Compare against the S&P 500 and review. See how the mix would have tracked the benchmark, then revisit as speculative positions move, since these names can change quickly.

In Walnut you create a thematic basket from securities you choose, set a target weight for each, see how the basket would track against the S&P 500, and place any trades you approve yourself at your own broker. Walnut does not recommend cannabis stocks or any other security.

To be clear about method, since framing matters most on a speculative category: this is not a prediction, not a ranking, and not a buy list. We did not forecast which cannabis names will recover or score them by expected return, because no one can do that reliably, and doing so on a sector this speculative would be misleading. We took a deliberately cautionary approach instead.

• Risks first. We led with federal illegality, 280E, banking, dilution, and OTC and delisting risk, because those define the category more than any single company does.
• Segments, not picks. We mapped the market into US operators, Canadian producers, ancillary names, micro-caps, and ETFs so you can see what you would be buying, and named companies only as examples of a segment.
• Adjacent alternatives. We pointed to lower-risk and more diversified ways to be near the theme, so the page teaches how to think about a speculative sector rather than which ticker to chase.

The result is a risk-forward map of the cannabis sector, not a shortlist of winners. Treat every name as a starting point for your own research, and verify current company facts and figures, which change quickly here, before you act.

The honest answer to “what are the best cannabis stocks” is that the sector is too speculative and has performed too poorly for any such list to mean much, which is why this page does not name picks. Cannabis is still federally illegal in the US, 280E taxation and the lack of normal banking crush profitability, many operators dilute holders to survive, and a large share of the group trades on OTC markets or faces delisting after falling more than 90% from its highs. If you research the sector anyway, understand the segments (US multi-state operators, Canadian licensed producers, ancillary names and REITs, and cannabis ETFs), keep any position small and diversified, and consider safer adjacent exposure instead of concentrating in a single speculative name. Walnut can help you turn that into a thematic basket you control and compare against your other holdings. It is informational and cautionary, is not an investment adviser, and nothing here is a recommendation.